Co-Authors
This is a "connection" page, showing publications co-authored by ELENI EFSTATHIOU and PATRICIA TRONCOSO.
Connection Strength
2.435
-
Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol. 2010 Jun; 57(6):1030-8.
Score: 0.351
-
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2021 02; 19(1):22-31.e5.
Score: 0.183
-
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2020 03; 127:67-75.
Score: 0.179
-
Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. Eur Urol. 2019 10; 76(4):418-424.
Score: 0.171
-
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. Eur Urol Oncol. 2020 02; 3(1):119-127.
Score: 0.170
-
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine. 2016 May; 7:85-93.
Score: 0.137
-
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015 Jan; 67(1):53-60.
Score: 0.121
-
Integrated Hedgehog signaling is induced following castration in human and murine prostate cancers. Prostate. 2013 Jan; 73(2):153-61.
Score: 0.106
-
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol. 2012 Feb 20; 30(6):637-43.
Score: 0.102
-
Expression of hedgehog pathway components in prostate carcinoma microenvironment: shifting the balance towards autocrine signalling. Histopathology. 2011 Jun; 58(7):1037-47.
Score: 0.098
-
Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1224-31.
Score: 0.073
-
The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progression. Medicine (Baltimore). 2021 Sep 10; 100(36):e27094.
Score: 0.050
-
Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res. 2021 06 01; 27(11):3253-3264.
Score: 0.048
-
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020 09 15; 26(18):4933-4946.
Score: 0.046
-
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Na?ve Metastatic Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):990-999.
Score: 0.045
-
Epigenetics and prostate cancer: defining the timing of DNA methyltransferase deregulation during prostate cancer progression. Pathology. 2020 Feb; 52(2):218-227.
Score: 0.044
-
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol. 2019 10; 20(10):1432-1443.
Score: 0.044
-
Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol. 2019 02; 21(1):86-94.
Score: 0.042
-
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med. 2017 May; 23(5):551-555.
Score: 0.037
-
Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci U S A. 2016 Nov 08; 113(45):12786-12791.
Score: 0.036
-
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. 2016 Jul 19; 7(29):46321-46334.
Score: 0.035
-
PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015 Jul 07; 112(27):8403-8.
Score: 0.032
-
Targeting the interleukin-11 receptor a in metastatic prostate cancer: A first-in-man study. Cancer. 2015 Jul 15; 121(14):2411-21.
Score: 0.032
-
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 03; 6(252):252ra122.
Score: 0.031
-
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal. 2014 May 20; 7(326):ra47.
Score: 0.030
-
Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One. 2012; 7(2):e31259.
Score: 0.026
-
Activation of ?-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res. 2012 Feb 01; 18(3):726-36.
Score: 0.026
-
Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer. Am J Pathol. 2012 Mar; 180(3):895-903.
Score: 0.026
-
Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012 Feb 01; 18(3):666-77.
Score: 0.025
-
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18637-42.
Score: 0.025
-
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011 Jun 20; 29(18):2574-81.
Score: 0.024
-
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 04; 101(5):306-20.
Score: 0.021
-
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008 Aug; 118(8):2697-710.
Score: 0.020